HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

seryl- leucyl- isoleucyl- glycyl- lysyl- valinamide

a proteinase-activated receptor agonist

Also Known As:

SLIGKV-NH2; Ser-Leu-Ile-Gly-Lys-Val-NH2

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - seryl-leucyl-isoleucyl-glycyl-lysyl-valinamide: 2

Experts

1.	Mrozkova, Petra: 1 article (01/2016)
2.	Palecek, Jiri: 1 article (01/2016)
3.	Spicarova, Diana: 1 article (01/2016)
4.	Chen, Li: 1 article (11/2012)
5.	Chen, Xiaoyi: 1 article (11/2012)
6.	Hai, Ou: 1 article (11/2012)
7.	Li, Fei: 1 article (11/2012)
8.	Li, Xuan: 1 article (11/2012)
9.	Xie, Liqun: 1 article (11/2012)
10.	Zhao, Junyan: 1 article (11/2012)

Related Diseases

1.	Hyperalgesia 01/01/2016 - "Intrathecal application of PAR2 activating peptide SLIGKV-NH2 induced thermal hyperalgesia, which was prevented by pretreatment with TRPV1 antagonist SB 366791 and was reduced by protein kinases inhibitor staurosporine. "
2.	Hepatocellular Carcinoma (Hepatoma) 11/01/2012 - "The results showed that PAR-2 is expressed in human hepatoma cells and PAR-2 mRNA expression was found to be upregulated in cells treated with trypsin or SLIGKV-NH2 (P<0.001). "

Related Drugs and Biologics

1.	Staurosporine
2.	Trypsin
3.	Messenger RNA (mRNA)
4.	Protein Kinases (Protein Kinase)
5.	Peptides (Polypeptides)
6.	N- (3- methoxyphenyl)- 4- chlorocinnamanilide